Medico Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
MEDICO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medico Remedies Limited submitted its Q1 FY26 standalone financial results for the quarter ended June 30, 2025, along with an unmodified limited review report from auditors V J Shah & Co. Revenue from operations rose to Rs. 3,825.15 lakhs from Rs. 3,079.81 lakhs in the same quarter last year, a year-on-year growth of about 24%. Profit after tax increased to Rs. 181.83 lakhs (vs Rs. 157.89 lakhs in Q1 FY25), translating to a basic EPS of Rs. 0.22. The company is heavily export-oriented, with overseas sales of Rs. 3,245.01 lakhs accounting for the bulk of revenue. Additionally, Mr. Hasan Bohra resigned as Company Secretary & Compliance Officer effective August 8, 2025, citing other professional commitments.
Strong revenue growth and steady profitability suggest the company is expanding well, though the PAT growth of around 15% lagged the topline surge, indicating some margin pressure. The simultaneous exit of the Company & Compliance Officer is a minor governance event investors should watch for timely replacement.